Shilpa Medicare Limited (SHILPAMED.BO)
INR 825.9
(-0.56%)
INR 825.9
(-0.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.18 Billion INR | -65.48% |
| 2022 | 6.31 Billion INR | 0.25% |
| 2021 | 6.3 Billion INR | 23.53% |
| 2020 | 5.1 Billion INR | 13.73% |
| 2019 | 4.48 Billion INR | 42.23% |
| 2018 | 3.15 Billion INR | 13.4% |
| 2017 | 2.78 Billion INR | 24.74% |
| 2016 | 2.22 Billion INR | 72.73% |
| 2015 | 1.29 Billion INR | -15.62% |
| 2014 | 1.52 Billion INR | 13.49% |
| 2013 | 1.34 Billion INR | 31.42% |
| 2012 | 1.02 Billion INR | 21.96% |
| 2011 | 840.88 Million INR | 23.68% |
| 2010 | 679.91 Million INR | 27.98% |
| 2009 | 531.28 Million INR | 24.63% |
| 2008 | 426.29 Million INR | 283.37% |
| 2007 | 111.19 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 539.63 Million INR | -7.12% |
| 2023 Q1 | 1.51 Billion INR | -8.86% |
| 2023 Q3 | 1.5 Billion INR | -2.56% |
| 2023 FY | 2.18 Billion INR | -65.48% |
| 2023 Q4 | 580.96 Million INR | -61.46% |
| 2023 Q2 | 1.54 Billion INR | 2.35% |
| 2022 Q2 | 1.57 Billion INR | -0.93% |
| 2022 Q4 | 1.65 Billion INR | 10.72% |
| 2022 FY | 6.31 Billion INR | 0.25% |
| 2022 Q1 | 1.59 Billion INR | -5.05% |
| 2022 Q3 | 1.49 Billion INR | -4.95% |
| 2021 FY | 6.3 Billion INR | 23.53% |
| 2021 Q2 | 1.59 Billion INR | 8.07% |
| 2021 Q1 | 1.47 Billion INR | -10.86% |
| 2021 Q3 | 1.56 Billion INR | -1.63% |
| 2021 Q4 | 1.67 Billion INR | 7.08% |
| 2020 Q3 | 1.2 Billion INR | 1.0% |
| 2020 FY | 5.1 Billion INR | 13.73% |
| 2020 Q1 | 1.05 Billion INR | 466.71% |
| 2020 Q2 | 1.19 Billion INR | 13.35% |
| 2020 Q4 | 1.65 Billion INR | 37.02% |
| 2019 Q4 | -286.98 Million INR | -126.01% |
| 2019 Q2 | 1.4 Billion INR | 57.66% |
| 2019 FY | 4.48 Billion INR | 42.23% |
| 2019 Q1 | 890.48 Million INR | 44.09% |
| 2019 Q3 | 1.1 Billion INR | -21.42% |
| 2018 Q2 | 895.68 Million INR | 7.68% |
| 2018 FY | 3.15 Billion INR | 13.4% |
| 2018 Q3 | 923.84 Million INR | 3.14% |
| 2018 Q1 | 831.8 Million INR | -8.11% |
| 2018 Q4 | 618 Million INR | -33.11% |
| 2017 FY | 2.78 Billion INR | 24.74% |
| 2017 Q3 | 762.22 Million INR | 7.02% |
| 2017 Q2 | 712.23 Million INR | 4.56% |
| 2017 Q1 | 681.16 Million INR | -15.86% |
| 2017 Q4 | 905.2 Million INR | 18.76% |
| 2016 Q1 | 545.78 Million INR | -8.6% |
| 2016 FY | 2.22 Billion INR | 72.73% |
| 2016 Q4 | 809.58 Million INR | 18.63% |
| 2016 Q3 | 682.43 Million INR | 13.41% |
| 2016 Q2 | 601.71 Million INR | 10.25% |
| 2015 Q4 | 597.11 Million INR | 12.5% |
| 2015 FY | 1.29 Billion INR | -15.62% |
| 2015 Q1 | 455.68 Million INR | 78.94% |
| 2015 Q2 | 525.67 Million INR | 15.36% |
| 2015 Q3 | 530.75 Million INR | 0.97% |
| 2014 Q2 | 434.01 Million INR | 9.88% |
| 2014 FY | 1.52 Billion INR | 13.49% |
| 2014 Q4 | 254.65 Million INR | -42.85% |
| 2014 Q3 | 445.6 Million INR | 2.67% |
| 2014 Q1 | 394.97 Million INR | 353.7% |
| 2013 Q2 | 440.45 Million INR | 10.4% |
| 2013 FY | 1.34 Billion INR | 31.42% |
| 2013 Q4 | 87.05 Million INR | -78.72% |
| 2013 Q3 | 409.06 Million INR | -7.13% |
| 2013 Q1 | 398.96 Million INR | 51.38% |
| 2012 FY | 1.02 Billion INR | 21.96% |
| 2012 Q2 | 218.43 Million INR | -19.18% |
| 2012 Q3 | 273.29 Million INR | 25.12% |
| 2012 Q1 | 270.26 Million INR | 50.79% |
| 2012 Q4 | 263.54 Million INR | -3.57% |
| 2011 FY | 840.88 Million INR | 23.68% |
| 2011 Q1 | 174.52 Million INR | 0.0% |
| 2011 Q4 | 179.22 Million INR | -30.4% |
| 2011 Q3 | 257.51 Million INR | 22.41% |
| 2011 Q2 | 210.37 Million INR | 20.55% |
| 2010 FY | 679.91 Million INR | 27.98% |
| 2009 FY | 531.28 Million INR | 24.63% |
| 2008 FY | 426.29 Million INR | 283.37% |
| 2007 FY | 111.19 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 92.842% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -98.418% |
| Sigachi Industries Limited | 579.88 Million INR | -276.037% |
| Bal Pharma Limited | 389.89 Million INR | -459.283% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -2.655% |
| Medico Remedies Limited | 161.84 Million INR | -1247.34% |
| Lasa Supergenerics Limited | 291.17 Million INR | -648.896% |
| Venus Remedies Limited | 1.91 Billion INR | -13.793% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 29.128% |
| Alpa Laboratories Limited | 156.14 Million INR | -1296.498% |
| Nectar Lifesciences Limited | 625.55 Million INR | -248.587% |
| Aarti Drugs Limited | 1.16 Billion INR | -86.778% |
| Lupin Limited | 95.67 Billion INR | 97.721% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 94.442% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 94.949% |
| Windlas Biotech Limited | 1 Billion INR | -116.649% |
| Suven Life Sciences Limited | 109.75 Million INR | -1886.869% |
| Eris Lifesciences Limited | 4.94 Billion INR | 55.885% |
| Valiant Laboratories Limited | 36.28 Million INR | -5908.953% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 74.093% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 52.386% |
| Ipca Laboratories Limited | 13.91 Billion INR | 84.329% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -53.647% |
| Achyut Healthcare Limited | 1.6 Million INR | -135424.487% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.586% |
| Bajaj HealthCare Limited | 985.34 Million INR | -121.302% |
| RPG Life Sciences Limited | 1.63 Billion INR | -33.329% |
| Mankind Pharma Limited | 23.15 Billion INR | 90.582% |
| Laurus Labs Limited | 3.01 Billion INR | 27.574% |
| Piramal Pharma Limited | 19.91 Billion INR | 89.05% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -131.387% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 89.821% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 86.259% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 96.773% |
| Unichem Laboratories Limited | 6.72 Billion INR | 67.579% |
| Sequent Scientific Limited | 2.9 Billion INR | 24.854% |
| Novartis India Limited | 470.1 Million INR | -363.856% |
| Wanbury Limited | 1.16 Billion INR | -87.832% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -55.447% |
| Wockhardt Limited | 6.4 Billion INR | 65.928% |
| Themis Medicare Limited | 782.85 Million INR | -178.543% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -181.945% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 84.914% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 81.268% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 97.726% |
| Divi's Laboratories Limited | 14.17 Billion INR | 84.611% |
| NATCO Pharma Limited | 10.05 Billion INR | 78.32% |
| Gufic Biosciences Limited | 1.07 Billion INR | -102.335% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -98.452% |
| Ind-Swift Limited | 946.56 Million INR | -130.368% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 27.202% |
| FDC Limited | 5.34 Billion INR | 59.23% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -4624.389% |
| Granules India Limited | 7.18 Billion INR | 69.64% |
| Medicamen Biotech Limited | 335.16 Million INR | -550.598% |
| Alkem Laboratories Limited | 32.83 Billion INR | 93.359% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 16.144% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -13352.372% |
| Brooks Laboratories Limited | 51.18 Million INR | -4160.627% |
| Megasoft Limited | 49.52 Million INR | -4302.74% |
| ZIM Laboratories Limited | 1.01 Billion INR | -115.248% |
| Strides Pharma Science Limited | 9.16 Billion INR | 76.2% |
| Neuland Laboratories Limited | 2.92 Billion INR | 25.571% |
| Morepen Laboratories Limited | 1.98 Billion INR | -9.718% |
| Hikal Limited | 2.48 Billion INR | 12.297% |
| Indoco Remedies Limited | 4.74 Billion INR | 54.081% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 29.073% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -428.721% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -222.502% |
| Hester Biosciences Limited | 908.84 Million INR | -139.931% |